Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3659-3671

  Van Voorhis, Wesley C ^a   Rivas, Kasey L ^a   Bendale, Pravin ^a   Nallan, Laxman ^a   Hornéy, Carolyn ^a   Barrett, Lynn K ^a   Bauer, Kevin D ^a   Smart, Brian P ^a   Ankala, Sudha ^a   Hucke, Oliver ^b   Verlinde, Christophe L M J ^b   Chakrabarti, Debopam ^c   Strickland, Corey ^d   Yokoyama, Kohei ^a   Buckner, Frederick S ^a   Hamilton, Andrew D ^e   Williams, David K ^f   Lombardo, Louis J ^f   Floyd, David ^g   Gelb, Michael H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e YALE UNIVERSITY   (United States)

^f BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^g PHARMACOPEIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLIMIDAZOLE; BMS 404683; BS 03; LN 16; LN 20; LN 25; LN 29; PB 102; PB 104; PB 17; PB 26; PB 27; PB 37; PB 43; PB 54; PB 80; PB 81; PB 93; PROPRANOLOL; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RANITIDINE; UNCLASSIFIED DRUG; VINBLASTINE; ZINC;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DEALKYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALARIA; MASS SPECTROMETER; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMALARIALS; BILE DUCTS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CRYSTALLOGRAPHY, X-RAY; DEALKYLATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MALARIA; MALE; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; MODELS, MOLECULAR; MUTAGENICITY TESTS; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 34948910649     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00246-07     Document Type: Article

References (32)

1. Basso, A. D., P. Kirschmeier, and W. R. Bishop. 2006. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 47:15-31.
2. Bendale, P., S. Olepu, P. K. Suryadevara, V. Bulbule, K. Rivas, L. Nallan, B. Smart, K. Yokoyama, S. Ankala, P. R. Pendyala, D. Floyd, L. J. Lombarde, D. K. Williams, F. S. Buckner, D. Chakrabarti, C. Verlinde, W. C. Van Voorhis, and M. H. Gelb. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as anti-malarials. J. Med. Chem., in press.
3. Carrico, D., J. Ohkanda, H. Kendrick, K. Yokoyama, M. A. Blaskovich, C. J. Bucher, F. S. Buckner, W. C. Van Voorhis, D. Chakrabarti, S. L. Croft, M. H. Gelb, S. M. Sebti, and A. D. Hamilton. 2004. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg. Med. Chem. 12:6517-6526.
4. Chakrabarti, D., T. Da Silva, J. Barger, S. Paquette, H. Patel, S. Patterson, and C. M. Allen. 2002. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem. 277:42066- 42073.
5. Eastman, R. T., F. S. Buckner, K. Yokoyama, M. H. Gelb, and W. C. Van Voorhis. 2006. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J. Lipid Res. 47:233-240.
6. Eastman, R. T., J. White, O. Hucke, K. Bauer, K. Yokoyama, L. Nallan, D. Chakrabarti, C. M. J. Verlinde, M. H. Gelb, and W. C. Van Voorhis. 2005. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J. Biol. Chem. 10:13554-13559.
7. Eastman, R. T., J. White, O. Hucke, K. Yokoyama, C. L. M. J. Verlinde, M. A. Hast, L. S. Beese, M. H. Gelb, P. K. Rathod, and W. C. Van Voorhis. 2007. Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol. Biochem. Parasitol. 152:66-71.
8. Fucik, K., K. Kettler, J. Wiesner, R. Ortmann, D. Unterreitmeier, J. Krauss, F. Bracher, H. Jomaa, and M. Schlitzer. 2004. 2-(Arylpropionylamino) - and 2-(arylacryloylamino)benzophenones: farnesyltransferase inhibition and antimalarial activity. Pharmazie 59:744-752.
9. Gelb, M. H., W. C. Van Voorhis, F. S. Buckner, K. Yokoyama, R. Eastman, E. P. Carpenter, C. Panethymitaki, K. A. Brown, and D. F. Smith. 2003. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. 126:155-163.
10. Glenn, M. P., S. Y. Chang, C. Horney, K. Rivas, K. Yokoyama, E. E. Pusateri, S. Fletcher, C. G. Cummings, F. S. Buckner, P. R. Pendyala, D. Chakrabarti, S. M. Sebti, M. Gelb, W. C. Van Voorhis, and A. D. Hamilton. 2006. Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J. Med. Chem. 49:5710-5727.
11. Hunter, J., B. H. Hirst, and N. L. Simmons. 1993. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:743-749.
12. Kettler, K., J. Wiesner, K. Fucik, J. Sakowski, R. Ortmann, H. M. Dahse, H. Jomaa, and M. Schlitzer. 2005. 2-(Aminoacylamino)benzophenones: farnesyltransferase inhibition and antimalarial activity. Pharmazie 60:677-682.
13. Kettler, K., J. Wiesner, K. Silber, P. Haebel, R. Ortmann, I. Sattler, H. M. Dahse, H. Jomaa, G. Klebe, and M. Schlitzer. 2005. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3- [5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity. Eur. J. Med. Chem. 40:93-10L
14. Kolars, J. C., P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins. 1992. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Investig. 90:1871-1878.
15. Lombarde, L. J., Camuso, A., J. Clark, K. Fager, J. Gullo-Brown, J. T. Hunt, I. Inigo, D. Kan, B. Kolowitz, F. Lee, K. McGlinchey, L. Qian, C. Ricca, G. Rovnyak, S. Traeger, J. Tokarski, D. K. Williams, L. I. Wu, Y. Zhao, V. Manne, and R. S. Bhide. 2005. Design, synthesis and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett. 15:1895-1899.
16. Maron, D. M., and B. N. Ames. 1983. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:173-215.
17. Nallan, L., K. D. Bauer, P. Bendale, K. Rivas, K. Yokoyama, C. P. Horney, P. R. Pendyala, D. Floyd, L. J. Lombardo, D. K. Williams, A. Hamilton, S. Sebti, W. T. Windsor, P. C. Weber, F. S. Buckner, D. Chakrabarti, M. H. Gelb, and W. C. Van Voorhis. 2005. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J. Med. Chem. 48:3704-3713.
18. Nwaka, S., and A. Hudson. 2006. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5:941-955.
19. Olliaro, P. 2005. Drug resistance hampers our capacity to roll back malaria. Clin. Infect. Dis. 41(Suppl. 4):S247-S257.
20. Ortmann, R., J. Wiesner, A. Reichenberg, D. Henschker, E. Beck, H. Jomaa, and M. Schlitzer. 2003. Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity. Bioorg. Med. Chem. Lett. 13:2163-2166.
21. Reichenberg, A., J. Wiesner, C. Weidemeyer, E. Dreiseidler, S. Sanderbrand, B. Altincicek, E. Beck, M. Schlitzer, and H. Jomaa. 2001. Diaryl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Bioorg. Med. Chem. Lett. 11:833-835.
22. Snow, R. W., C. A. Guerra, A. M. Noor, H. Y. Myint, and S. I. Hay. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217.
23. Strickland, C. L., P. C. Weber, W. T. Windsor, Z. Wu, H. V. Le, M. M. Albanese, C. S. Alvarez, D. Cesarz, J. del Rosario, J. Deskus, A. K. Mallams, F. G. Njoroge, J. J. Piwinski, S. Remiszewski, R. R. Rossman, A. G. Taveras, B. Vibulbhan, R. J. Doll, V. M. Girijavallabhan, and A. K. Ganguly. 1999. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J. Med. Chem. 42:2125-2135.
24. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
25. van Breemen, R. B., and Y. Li. 2005. Caco-2 cell permeability assays to measure drug absorption. Expert. Opin. Drug Metab. Toxicol. 1:175-185.
26. Watkins, P. B., S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S. Guzelian. 1987. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Investig. 80:1029-1036.
27. WHO. 2005. WHO world malaria report. WHO, Geneva, Switzerland.
28. Wiesner, J., K. Fucik, K. Kettler, J. Sakowski, R. Ortmann, H. Jomaa, and M. Schlitzer. 2003. Structure-activity relationships of novel anti-malarial agents. Part 6. N-(4-arylpropionylamino-3-benzoylphenyl)- [5-(4-nitrophenyl)-2-furyl]acrylic acid amides. Bioorg. Med. Chem. Lett. 13:1539-1541.
29. Wiesner, J., K. Kettler, J. Sakowski, R. Ortmann, A. M. Katzin, E. A. Kimura, K. Silber, G. Klebe, H. Jomaa, and M. Schlitzer. 2004. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew. Chem. Int. Ed. Engl. 43:251-254.
30. Wiesner, J., A. Mitsch, M. Altenkamper, R. Ortmann, H. Jomaa, and M. Schlitzer. 2003. Structure-activity relationships of novel anti-malarial agents. Part 8. Effect of different central aryls in biarylacryloylaminobenzophenones on antimalarial activity. Pharmazie 58:854-856.
31. Wiesner, J., R. Ortmann, H. Jomaa, and M. Schlitzer. 2003. New antimalarial drugs. Angew. Chem. Int. Ed. Engl. 42:5274-5293.
32. Wiesner, J., R. Ortmann, A. Mitsch, P. Wissner, I. Sattler, H. Jomaa, and M. Schlitzer. 2003. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity. Pharmazie 58:289-290.